Effect of Fiasp® in Type 1 Diabetes Treatment

Diabetes Mellitus, Type 1 Clinical Trial

Official title:

The Effect of Fiasp® (Fast-acting Insulin Aspart) in Type 1 Diabetes Patients Using Continuous Glucose Monitoring / Flash Glucose Monitoring in Real-world Clinical Practice in Sweden. A Non-interventional, Retrospective Chart and Database Review Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03895515
• Other study ID #: NN1218-4510
• Secondary ID: U1111-1228-4256
• Status: Completed
• Start date: January 3, 2020
• Est. completion date: December 21, 2020

Study information

• Verified date: April 2022
• Source: Novo Nordisk A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Fiasp® is a meal-time insulin that has been available in Sweden since June 2017. This study will investigate the effectiveness of Fiasp® in treating Type 1 Diabetes Mellitus. The study will be based on blood sugar measurements that the participants have uploaded to the Diasend® database and on existing data in their electronic medical records. The study does not require any additional visits to the study doctor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 178
• Est. completion date: December 21, 2020
• Est. primary completion date: December 21, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion criteria:

• Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study (beyond identification of potential participants by searching for patients with type 1 Diabetes diagnosis, Fiasp® prescription information and electronic medical record (EMR) data to identify continuous glucose monitoring (CGM)/flash glucose monitoring (FGM) use

• Age greater than or equal to 18 years at the time of signing informed consent

• Switched to a basal-bolus insulin regimen with Fiasp® as the bolus insulin, from a basal-bolus insulin regimen with any other bolus insulin. Switch must have occurred greater than or equal to 26 weeks prior to data collection and during 01 September 2017 to 31 August 2018

• Treated with basal-bolus insulin regimen throughout the 26 weeks prior to Fiasp® initiation

• Treated with the same basal insulin, i.e. no records of switching the basal insulin, during the 26 weeks prior to Fiasp® initiation or the 26 weeks after Fiasp® initiation

• Diagnosed with type 1 diabetes for greater than or equal to 12 months prior to Fiasp® initiation

• Use of CGM/FGM during the 26 weeks prior to Fiasp® initiation and the 26 weeks after Fiasp® initiation

• Use of the same CGM/FGM device during the full 26-week period after Fiasp® initiation.

Exclusion criteria:

• Previous participation in this study. Participation is defined as signed informed consent

• Participation in clinical study with receipt of any investigational medicinal product known to affect glucose control during the 26-week period prior to Fiasp® initiation or the 26-week period after Fiasp® initiation

• Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation

• Patients prescribed any other glucose-lowering drugs than insulins (anatomical therapeutic chemical [ATC] class A10B), including oral and injectable drugs, as addition to their insulin treatment during the 26-week period prior to Fiasp® initiation or the 26-week period after Fiasp® initiation

• Use of Fiasp® as bolus insulin during the 26-week period prior to Fiasp® initiation

• Use of any insulin with an insulin pump (i.e. continuous subcutaneous insulin infusion) during the 26-week period prior to Fiasp® initiation or the 26-week period after Fiasp® initiation.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1

Intervention

Drug:
• Fiasp®
Participants receive treatment with Fiasp® according to routine clinical practice. All treatment decisions, including assignment of participants to Fiasp® treatment, were made independently of the study and prior to the participants' inclusion in the study.

Locations

Country	Name	City	State
Sweden	Novo Nordisk Investigational Site	Stockholm

Sponsors (1)

Lead Sponsor	Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in percentage of time spent in glycaemic target range (TIR)	Measured in percentage point.; The change in percentage of TIR was defined as a blood glucose level of 3.9 to 10.0 mmol/L after initiation of Fiasp® treatment. Index date is first Fiasp® prescription between 01 Sep 2017 and 01 Sep 2018.; Time frame description: From: Closest continuous two-week period during the four weeks before the index date To: Continuous two-week period available closest to Week 26 during a period ranging between 20 weeks after index date to 32 weeks after index date. Measurements will, irrespective of analysis, only be considered if the patient is concomitantly on Fiasp® treatment.	Two-week period closest to and before index date, Two-week period closest to Week 26
Secondary	Change in mean sensor glucose	Measured in mmol/L; Index date is first Fiasp® prescription between 01 Sep 2017 and 01 Sep 2018.; Time frame description: From: Closest continuous two-week period during the four weeks before the index date To: Continuous two-week period available closest to Week 26 during a period ranging between 20 weeks after index date to 32 weeks after index date. Measurements will, irrespective of analysis, only be considered if the patient is concomitantly on Fiasp® treatment.	Two-week period closest to and before index date, Two-week period closest to Week 26
Secondary	Change in glycaemic variability (GV) (measured as coefficient of variation [CV])	Measured in percentage point; Index date is first Fiasp® prescription between 01 Sep 2017 and 01 Sep 2018.; Time frame description: From: Closest continuous two-week period during the four weeks before the index date To: Continuous two-week period available closest to Week 26 during a period ranging between 20 weeks after index date to 32 weeks after index date. Measurements will, irrespective of analysis, only be considered if the patient is concomitantly on Fiasp® treatment.	Two-week period closest to and before index date, Two-week period closest to Week 26
Secondary	Change in percentage of time spent in level 1 hyperglycaemia (greater than 10.0 mmol/L)	Measured in percentage point; Index date is first Fiasp® prescription between 01 Sep 2017 and 01 Sep 2018.; Time frame description: From: Closest continuous two-week period during the four weeks before the index date To: Continuous two-week period available closest to Week 26 during a period ranging between 20 weeks after index date to 32 weeks after index date. Measurements will, irrespective of analysis, only be considered if the patient is concomitantly on Fiasp® treatment.	Two-week period closest to and before index date, Two-week period closest to Week 26
Secondary	Change in percentage of time spent in level 2 hyperglycaemia (greater than 13.9 mmol/L)	Measured in percentage point; Index date is first Fiasp® prescription between 01 Sep 2017 and 01 Sep 2018.; Time frame description: From: Closest continuous two-week period during the four weeks before the index date To: Continuous two-week period available closest to Week 26 during a period ranging between 20 weeks after index date to 32 weeks after index date. Measurements will, irrespective of analysis, only be considered if the patient is concomitantly on Fiasp® treatment.	Two-week period closest to and before index date, Two-week period closest to Week 26
Secondary	Change in percentage of time spent in level 2 hypoglycaemia (lesser than 3.0 mmol/L)	Measured in percentage point; Index date is first Fiasp® prescription between 01 Sep 2017 and 01 Sep 2018.; Time frame description: From: Closest continuous two-week period during the four weeks before the index date To: Continuous two-week period available closest to Week 26 during a period ranging between 20 weeks after index date to 32 weeks after index date. Measurements will, irrespective of analysis, only be considered if the patient is concomitantly on Fiasp® treatment.	Two-week period closest to and before index date, Two-week period closest to Week 26
Secondary	Change in percentage of time spent in level 1 hypoglycaemia (lesser than 3.9 mmol/L)	Measured in percentage point; Index date is first Fiasp® prescription between 01 Sep 2017 and 01 Sep 2018.; Time frame description: From: Closest continuous two-week period during the four weeks before the index date To: Continuous two-week period available closest to Week 26 during a period ranging between 20 weeks after index date to 32 weeks after index date. Measurements will, irrespective of analysis, only be considered if the patient is concomitantly on Fiasp® treatment.	Two-week period closest to and before index date, Two-week period closest to Week 26
Secondary	Proportion with CV lesser than 36%	Proportion of participants with/without GV corresponding to a CV lesser than 36%; Time frame description: Continuous two-week period available closest to Week 26 during a period ranging between 20 weeks after index date to 32 weeks after index date. Measurements will, irrespective of analysis, only be considered if the patient is concomitantly on Fiasp® treatment.	Two-week period closest to Week 26
Secondary	Change in Glycated Haemoglobin A1c (HbA1c)	Measured in mmol/mol; Index date is first Fiasp® prescription between 01 Sep 2017 and 01 Sep 2018.; Measurement closest to Week 26 will be identified from a period ranging between 12 weeks after index date and 32 weeks after index date	Latest measurement between Week -12 and index date, measurement closest to Week 26